Patents Assigned to Sangamo Therapeutics, Inc.
  • Compositions for linking DNA-binding domains and cleavage domains
    Patent number: 11041174
    Abstract: Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases. Also described are methods of making and using compositions comprising these linkers.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: June 22, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: David Paschon, Lei Zhang
  • IMPROVED CLINICAL PARAMETERS BY EXPRESSION OF FACTOR VIII
    Publication number: 20210171982
    Abstract: Described herein are constructs used for liver-specific expression of a transgene.
    Type: Application
    Filed: August 2, 2019
    Publication date: June 10, 2021
    Applicant: Sangamo Therapeutics, Inc.
    Inventors: Edward R. Conner, Brigit E. Riley, Didier Rouy
  • Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
    Patent number: 11020492
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted integration of a functional SCID-related genes (e.g., IL2RG, RAG1 and/or RAG2 gene) into an IL2RG gene of a cell for provision of proteins lacking or deficient in SCID.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: June 1, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Anthony Conway
  • Nuclease-mediated regulation of gene expression
    Patent number: 11021696
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: June 1, 2021
    Assignees: Children's Medical Center Corporation, Sangamo Therapeutics, Inc.
    Inventors: Stuart H. Orkin, Andreas Reik, Fyodor Urnov
  • Methods and compositions for regulation of transgene expression
    Patent number: 10975375
    Abstract: Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: April 13, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Engineered target specific nucleases
    Patent number: 10975393
    Abstract: Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: April 13, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar
  • Methods and compositions for genome engineering
    Patent number: 10968261
    Abstract: Disclosed herein are methods and compositions for insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: April 6, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, David Paschon, Edward J. Rebar, Thomas Wechsler, Lei Zhang
  • Modulation of liver genes
    Patent number: 10960085
    Abstract: Described herein are compositions and methods for modulation of gene expression in the liver including modulation of PCSK9, TTR, SERPINA1, KLKB1 and/or HAO1.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: March 30, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Gary K. Lee, David Paschon, Lei Zhang
  • FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
    Patent number: 10961540
    Abstract: A method of gene editing or gene stacking within a FAD3 loci by cleaving, in a site directed manner, a location in a FAD3 gene in a cell, to generate a break in the FAD3 gene and then ligating into the break a nucleic acid molecule associated with one or more traits of interest is disclosed.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: March 30, 2021
    Assignees: Dow AgroSciences LLC, Sangamo Therapeutics, Inc.
    Inventors: Noel Cogan, John Forster, Matthew Hayden, Tim Sawbridge, German Spangenberg, Steven R. Webb, Manju Gupta, W. Michael Ainley, Matthew J. Henry, Jeffrey C. Miller, Dmitry Y. Guschin
  • Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
    Patent number: 10918668
    Abstract: Disclosed herein are methods and compositions for modifying TCR genes, using nucleases (zinc finger nucleases or TAL nucleases) to modify TCR genes.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: February 16, 2021
    Assignees: Sangamo Therapeutics, Inc., Ospedale San Raffaele SRL
    Inventors: Philip D. Gregory, Michael C. Holmes, David Paschon, Lei Zhang, Maria Chiara Bonini, Pietro Genovese, Zulma Magnani, Sara Mastaglio, Luigi Naldini
  • Isolated human cell with an inactivated glucocorticoid receptor gene
    Patent number: 10907175
    Abstract: Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR. Such methods and compositions are useful, for example, in therapeutic applications which require retention of immune function during glucocorticoid treatment.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: February 2, 2021
    Assignees: Sangamo Therapeutics, Inc., City of Hope
    Inventors: Andreas Reik, Michael Jensen, Michael C. Holmes, Philip D. Gregory, Dale Ando
  • Separation and Quantification of Empty and Full Viral Capsid Particles
    Publication number: 20210009964
    Abstract: The present disclosure provides methods for the separation and quantification of empty and full viral capsids (e.g., AAV capsids) within a viral preparation, such as a viral pharmaceutical composition or drug product.
    Type: Application
    Filed: July 12, 2020
    Publication date: January 14, 2021
    Applicant: Sangamo Therapeutics, Inc.
    Inventors: Santoshkumar Khatwani, Zhu Pirot
  • Methods and compositions for enhancing targeted transgene integration
    Patent number: 10889834
    Abstract: Disclosed herein are methods and compositions for enhancing insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease or a hemophilia by administering one or more topoisomerases inhibitors, one or more stabilizers of R loop formation or inhibitors of R-loop repair and/or one or more up-regulators of the TC-NER pathway to the target cell.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: January 12, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gregory J. Cost, Thomas Wechsler
  • Modulation of stem cells using zinc finger proteins
    Patent number: 10888589
    Abstract: Methods and compositions for modifying stem cells using one or more ZFPs are disclosed. Such methods and compositions are useful for facilitating processes such as, for example, dedifferentiating cells, differentiating stem cells into the desired phenotype, propagating stem cells and/or facilitating cloning.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: January 12, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Alan P. Wolffe, Michael Moore, Timothy Farries, Trevor Collingwood, Fyodor Urnov
  • Methods and compositions for delivery of biologics
    Patent number: 10883119
    Abstract: Nucleases and methods of using these nucleases for genetic alteration of red blood cells (RBCs), for example for providing for a protein lacking in a monogenic disorder or a biologic for the treatment of exposure to a toxin using genetically altered RBCs.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: January 5, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Gregory J. Cost
  • Methods and compositions for treating Huntington's disease
    Patent number: 10857203
    Abstract: Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: December 8, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar, H. Steve Zhang
  • Methods and compositions for modification of a HLA locus
    Patent number: 10858416
    Abstract: Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: December 8, 2020
    Assignees: Sangamo Therapeutics, Inc., Board of Regents, The University of Texas System
    Inventors: Trevor Collingwood, Laurence J. N. Cooper, Philip D. Gregory, Michael C. Holmes, Jeffrey C. Miller, Edward J. Rebar, Andreas Reik, Fyodor Urnov
  • Controlled Transgene Expression in Regulatory T Cells
    Publication number: 20200368279
    Abstract: The present disclosure provides mammalian cells such as regulatory T cells containing a transgene in the FOXP3 genomic locus. Also provided are methods of generating the cells and methods of using the cells to treat patients in need of immunosuppression.
    Type: Application
    Filed: May 21, 2020
    Publication date: November 26, 2020
    Applicant: Sangamo Therapeutics, Inc.
    Inventor: Anthony Conway
  • FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
    Patent number: 10844389
    Abstract: Methods and compositions for gene disruption, gene editing or gene stacking within a FAD2 loci by cleaving, in a site directed manner, a location in a FAD2 gene in a soybean cell, to generate a break in the FAD2 gene and then optionally integrating into the break a nucleic acid molecule of interest is disclosed.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: November 24, 2020
    Assignees: Dow AgroSciences LLC, Sangamo Therapeutics, Inc.
    Inventors: W. Michael Ainley, Steven R. Webb, Jayakumar P. Samuel, Dmitry Y. Guschin, Jeffrey C. Miller, Lei Zhang
  • Method of inactivating the IPK1 gene in corn
    Patent number: 10827731
    Abstract: Disclosed herein are homozygously modified organisms and methods of making and using these organisms.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: November 10, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Yannick Doyon